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Introduction
Asthma is a complex heritable inflammatory disorder of the
airways associated with airway obstruction as well as a
variety of clinical signs [1,2]. Airway hyperresponsiveness
(AHR), a risk factor and a cardinal feature of asthma, is
characterized as an exaggerated airway response to an irri-
tant stimulus, resulting in airway obstruction. Asthma is
commonly associated with chronic elevation of serum IgE,
another risk factor for the disorder, which is closely associ-
ated with allergy. Allergic asthma (atopic asthma) is the
most common, accounting for 90% of cases under
30 years of age [3]. In addition, asthmatics frequently suffer
from mucus overproduction that is thought to contribute to
airway obstruction. Although allergic agents are numerous
and the inflammatory responses produced are complex,
clinical and experimental studies have strongly suggested
the involvement of T helper type 2 (TH2) lymphocytes, and
the cytokines that they produce, in the pathogenesis of
allergic asthma [4,5]. Other forms of asthma include those
induced by exercise, viruses, aspirin, and occupation. The
mechanism underlying these forms of asthma might simi-
larly involve TH2 lymphocytes and cytokines but might be
triggered differentially by airway epithelium damage caused
by viral infection, excess leukotriene production, or water
loss that in turn stimulates the release of histamine by mast
cells and basophils [6–9]. One rational approach to creat-
ing novel medications for asthma is to identify the underly-
ing biological mechanisms to treat the root cause, not just
the symptoms.
Genetic epidemiology confirms that there is a strong heri-
table component to asthma [2]. Genetic mapping studies
reveal that chromosome 5q31–q33 is of particular interest
because it contains the cytokine gene cluster including
interleukin (IL)-4, IL-5, IL-9, IL-13, and numerous growth
factors and receptors implicated in allergic inflammation
[10]. Because of the enormous body of literature demon-
strating the important roles of these cytokines in biological
responses associated with asthma, emphasis has previ-
ously focused on strategies to inhibit the activity of IL-4
and IL-5 [11]. However, the crucial roles of these factors
in supporting the normal biology of specific cell types
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suggest that blocking their activity might compromise
normal host defense. Recently, IL-9 and IL-13 have been
shown to mediate AHR in the allergic lung, and blockage
of either cytokine by using neutralizing antibody or soluble
receptor is sufficient to attenuate AHR in selective animal
models [12–17]. In this review we examine recent evi-
dence supporting a central role for IL-9 as a critical media-
tor of allergic asthma, comparing these data with similar
studies on IL-4, IL-5, and IL-13.
IL-9 is a TH2 cytokine that has pleiotropic
effects on various cell types important in the
pathogenesis of asthma
IL-9 was originally described as a mast cell growth factor
for its ability to enhance the survival of primary mast cells
and to induce their production of the inflammatory
cytokine IL-6 [18,19]. IL-9 also stimulates the production
of mast cell proteases and the high-affinity IgE receptor
(FceRIa), suggesting that IL-9 primes mast cells to
respond to allergen via increased cell surface expression
of the high-affinity IgE receptor and the production of
inflammatory mediators including IL-6 and several pro-
teases [20]. IL-9 was cloned as a T-cell growth factor for
its ability to support antigen-independent growth of
T helper clones [21,22]. Expression studies in vitro show
that IL-9 could be produced by TH2-type lymphocytes,
making it a member of the TH2 cytokine family [18]. In
addition, studies of immunoglobulin production in vitro by
B cells demonstrated that IL-9 enhances the IL-4-medi-
ated production of IgE in human and murine B cells [23].
Recently, IL-9 has been shown to promote eosinophil mat-
uration in synergy with IL-5 [24]. IL-9 modulates the
expression of IL-5Ra in myeloid precursor cell lines
[25,26]. IL-9 might therefore induce airway eosinophilia
through the upregulation of IL-5 response and potentiating
the IL-5-mediated maturation of eosinophil precursors
[25,26]. Furthermore, IL-9 has been shown to activate
airway epithelial cells by stimulating the production of
several chemokines, proteases, ion channels and selective
mucin genes [27,28]. Longphre et al [29] concluded, on
the basis of studies in vitro and in vivo, that IL-9, but not
IL-5 or IL-13, might account for most of the mucin-stimula-
tory activity of lung fluids in allergic airway disease. Taken
together, these results indicate that IL-9 has pleiotropic
activities on various cell types that are important in the
pathogenesis of asthma. It is noteworthy that, unlike the
IL-4-mediated production of IgE by B cells, or the IL-5-
induced maturation of eosinophils, IL-9 seems to act pri-
marily by enhancing the activities of many other cytokines
and factors [23,28]. Blockage of its activity is therefore
less likely to compromise normal host defense.
Genetic studies that identify the gene
encoding IL-9 as a candidate gene for asthma
Asthma is an ecogenetic disorder in which the genetic
background influences the environmental response [30].
Genetic mapping studies with asthma families identified
several chromosomal regions that seem to harbor genes
determining susceptibility to asthma and related risk
factors including AHR and serum IgE [31–36]. Chromo-
some 5q31–q33 is one location in which asthma and its
risk factors have been mapped by genetic linkage
[10,34,35]. Chromosome 5q31–q33 contains numerous
genes, such as those for cytokines, growth factors, and
receptors, that are potentially involved in airway inflamma-
tion and atopic asthma [10]. Structural analyses of these
candidate genes have identified polymorphisms in the pro-
moter regions or coding regions of IL-4, IL-9, and IL-13
that are thought to alter gene regulation or function, and
are potentially associated with atopy and asthma [37,38].
Significant biological variability in airway responsiveness in
rodents has also been observed [39,40]. Linkage studies
in mice associate AHR with a small region on chromo-
some 13 where the IL-9 gene is located [40]. This region
is homologous with chromosome 5q31–q33 in humans
[40]. In contrast, the cytokine genes encoding IL-4, IL-5,
and IL-13 map to the syntenic region of mouse chromo-
some 11, excluding the linkage of these candidates in the
mouse. Analyses of the murine IL-9 gene identified a
genetic defect at the C57BL/6 (B6) IL-9 locus associated
with no detectable lung IL-9 expression and reduced
airway responsiveness in naive B6 mice. In contrast,
robust expression of IL-9 gene and protein in the lung was
observed in DBA/2J mice associated with AHR. Further-
more, (B6D2)F1 mice were intermediate in airway respon-
siveness and lung IL-9 levels, demonstrating a tight
genotype–phenotype relation. These inbred strains
showed no difference in IL-4 or IL-5 expression levels in
the lung [40]. This naturally occurring variant, which lacks
IL-9 (B6 mice), is healthy and does not seem to be
immunocompromised. Thus, whereas IL-9 seems to act
primarily by enhancing the activity of many other cytokines
and chemokines, B6 mice suggest that it is dispensable.
Human studies corroborate these animal data. Elevated
IL-9 expression, as determined by immunocytochemistry
and in situ hybridization, demonstrated a highly significant
and specific association between the expression of this
cytokine with asthma and AHR ([41], and D Robinson,
personal communication). Thus, IL-9 seems to be impor-
tant in regulating the known risk factors for asthma, and
represents an important target identified through genetic
means for therapeutic intervention in this disorder.
IL-9 transgenic mice and recombinant IL-9
instillation in B6 mice provide further
evidence for a role in asthma development
Two independent IL-9 transgenic models have been
developed that indicate that the overexpression of IL-9 has
a profound disturbance on hematopoietic cell lineages
[15,42]. Systemic expression of an IL-9 transgene hasRespiratory Research    Vol 2 No 2 Zhou et al
been associated with lymphomagenesis, expansion of B-1
lymphocytes, enhanced IgE production, mastocytosis, and
parasitic worm expulsion [42–45]. Both transgenic models,
one with systemic expression, the other with expression of
an IL-9 transgene controlled by a lung-specific promoter
(CC-10 promoter), led to a phenotype consistent with
asthma. This phenotype included mucus overproduction,
sub-epithelial fibrosis, increased intra-epithelial mast cells,
lung eosinophilia, elevated IgE levels, AHR, and increased
responsiveness to antigen stimulation [12,15]. In contrast,
overexpression of IL-4 with the CC-10 promoter resulted in
baseline eosinophilia without AHR [46]. Overexpression of
IL-13 in a similar model led to baseline AHR, eosinophilia,
and mucus overproduction. However, bronchoalveolar
lavage (BAL) fluid from IL-13 transgenic mice also con-
tained mononuclear cells and enlarged multinucleate cells
(a cell type not usually associated with human asthma),
suggesting biological effects on granulocytes [47]. Mast
cells are also important effector cells in asthma, and
increased numbers of intra-epithelial lung mast cells were a
noteworthy, apparently unique, finding in both strains of IL-
9 transgenic mice [15,42]. Moreover, mast cells isolated
from IL-13–/– transgenic knockouts were able to secrete
levels of IL-4 and IL-5 that were equivalent to wild-type
mast cells [48]. These data therefore suggest that IL-13 is
not important in mast cell biology.
To elucidate further the temporal and spatial requirement
of IL-9 in vivo on the pathophysiology of asthma, studies
were made on recombinant mouse IL-9 (rIL-9) instilled into
the airways of B6 mice, which had previously been shown
to be genetically deficient in lung IL-9 protein [26]. Lung
instillation of rIL-9 for up to 10 days produced all the
histopathological features of asthma, including a time-
dependent and dose-dependent increase in AHR, BAL
eosinophils, total serum IgE, and lung proteases, along
with submucosal membrane thickening [26]. Consistent
with observations in IL-9 transgenic animals, increased
mucus production in the rIL-9 instilled lung was associ-
ated with the specific upregulation of MUC2 and
MUC5AC mucin gene products [28]. Collectively, these
results suggest that IL-9 is sufficient to produce a classi-
cal TH2 response in vivo, and regulates AHR, lung
eosinophilia, and serum total IgE.
Comparisons with mice instilled intratracheally with IL-13
demonstrated both similarities and some notable differ-
ences [49]. Mice similarly treated with IL-13 or IL-9
showed increased allergic inflammation, AHR, and
mucous cell metaplasia, and induction of genes encoding
lung chemokines, proteases, adhesion molecules, and
mucins. Compared with mice receiving IL-9, mice treated
with IL-13 had a greater cellular influx and inflammation-
related gene upregulation at lower IL-13 doses and after
fewer intratracheal instillations. Although IL-13 instillation
caused eosinophil and lymphocyte influx into the lung, it
was unique in its ability to recruit neutrophils as the domi-
nant cell type. IL-9 administration resulted in eosinophil
and lymphocyte infiltration without neutrophilia. At similar
doses, both IL-9 and IL-13 produced comparable mucous
metaplasia after only 3 days of instillations.
IL-9-neutralizing antibody ablates the
asthmatic response without compromising
the normal host defense system
Neutralizing antibodies or soluble receptors have been suc-
cessful strategies for demonstrating the involvement of IL-
4, IL-5, and IL-13 in asthmatic responses [13,14,50].
Recently, two studies using IL-9 neutralizing antibody con-
firmed that IL-9 is a necessary mediator of asthma [16,17].
In one of the models, IL-9-neutralizing antibody was
instilled directly into the lungs of mice exposed to either
Aspergillus fumigatus or dust mite antigen. In these asthma
models of mucosal TH2 immunity, A. fumigatus or dust mite
antigen produced a marked allergic inflammatory response
in (B6D2)F1 mice, including significant increases in BAL
eosinophils, elevated serum total IgE, increased mucin pro-
duction, and AHR in comparison with control or naive
animals. Intratracheal administration of IL-9-neutralizing
antibody reduced the constellation of allergic inflammation
in these models including AHR, serum total IgE elevations,
and increases in BAL eosinophils in comparison with treat-
ments of isotype-specific control antibody or untreated
sensitized mice. Alcian Blue/PAS stains for mucus and
overall histopathologic grading confirmed that the antibody
treatment effectively abrogated the allergic asthmatic
response in the antigen-challenged animals [16]. An inde-
pendent study showed that similar blockage results from
systematic administration of an IL-9 neutralization antibody
in ovalbumin-treated BALB/c mice [17]. Taken together,
these results demonstrate that IL-9 is both necessary and
sufficient to produce the asthmatic response.
Most recently, the first IL-9-deficient mice were reported as
being healthy with no overall development abnormalities or
phenotype [51]. Naive cytokine profiles, TH1 and TH2 cell
development, and generation of naive or antigen-specific
antibody responses were all normal in IL-9-deficient mice.
Using a primary pulmonary granulomatous model induced
by Schistosoma mansoni eggs, the authors demonstrated
a transient reduction in mucus production and lung mast
cell numbers in the IL-9-deficient mice, indicating a funda-
mental role of IL-9 in the rapid and robust pulmonary
mucus production and mastocytosis in response to lung
challenge. Otherwise, IL-9-deficient mice developed
normal granulomas with eosinophilia. Lymph nodes from IL-
9-deficient mice expressed normal levels of IL-4, IL-5, and
IL-13. In addition, the requirement for IL-9 in the expulsion
of the intestinal parasitic nematode Nippostrongylus
brasiliensis, as previously suggested in the IL-9 transgenic
mice, was completely compensated for by increased
expression of IL-4 and IL-5 [51]. However, in marked con-trast to the specific reduction in goblet cell and mast cell
responses observed in IL-9-deficient mice in the pulmonary
granulomatous model, IL-13-deficient mice developed a
global downregulation of the TH2 response with smaller
granulomas around S. mansoni eggs, a reduction in lung
eosinophilia, and reduced IL-4, IL-5, and IL-9 productions
from cultured lymph nodes [51], indicating a role for IL-13
as a general enhancing factor on TH2 response.
Conclusion
IL-9 was first suggested as an asthma candidate gene by
unbiased genetic mapping studies on AHR and linkage
homology in both humans and mice. Cell biology in vitro
has shown that IL-9 is an important growth factor and
stimulator of numerous cell types important in the patho-
genesis of asthma. Mice overexpressing IL-9 and neutraliz-
ing antibodies further demonstrate a crucial role for IL-9 in
the development of the allergic asthmatic response.
Importantly, increased lung IL-9 expression in mice and
humans is tightly and specifically associated with asthma
and its risk factors; decreased IL-9 is protective from
antigen challenge. IL-9-deficient animals, including natu-
rally occurring mutants and transgenic knockout mice, are
healthy, suggesting that IL-9 therapeutic intervention will
be well tolerated. Thus, IL-9 seems to be both necessary
and sufficient to produce the TH2 response in vivo and is
an important therapeutic target for allergic asthma.
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